208 related articles for article (PubMed ID: 8720577)
1. Morphine-induced catalepsy is augmented by NMDA receptor antagonists, but is partially attenuated by an AMPA receptor antagonist.
Tzschentke TM; Schmidt WJ
Eur J Pharmacol; 1996 Jan; 295(2-3):137-46. PubMed ID: 8720577
[TBL] [Abstract][Full Text] [Related]
2. The AMPA receptor antagonist GYKI 52466 reverses the anti-cataleptic effects of the competitive NMDA receptor antagonist CGP 37849.
Hauber W; Waldenmeier MT
Eur J Pharmacol; 1994 May; 256(3):339-42. PubMed ID: 7913894
[TBL] [Abstract][Full Text] [Related]
3. The non-NMDA glutamate receptor antagonist GYKI 52466 counteracts locomotor stimulation and anticataleptic activity induced by the NMDA antagonist dizocilpine.
Hauber W; Andersen R
Naunyn Schmiedebergs Arch Pharmacol; 1993 Nov; 348(5):486-90. PubMed ID: 8114947
[TBL] [Abstract][Full Text] [Related]
4. The role of NMDA and AMPA/Kainate receptors in the consolidation of catalepsy sensitization.
Riedinger K; Kulak A; Schmidt WJ; von Ameln-Mayerhofer A
Behav Brain Res; 2011 Mar; 218(1):194-9. PubMed ID: 21130808
[TBL] [Abstract][Full Text] [Related]
5. Effects of NMDA receptor antagonists on inhibition of morphine tolerance in rats: binding at mu-opioid receptors.
Wong CS; Cherng CH; Luk HN; Ho ST; Tung CS
Eur J Pharmacol; 1996 Feb; 297(1-2):27-33. PubMed ID: 8851162
[TBL] [Abstract][Full Text] [Related]
6. Interactions of MK-801 and GYKI 52466 with morphine and amphetamine in place preference conditioning and behavioural sensitization.
Tzschentke TM; Schmidt WJ
Behav Brain Res; 1997 Mar; 84(1-2):99-107. PubMed ID: 9079776
[TBL] [Abstract][Full Text] [Related]
7. N-methyl-D-aspartic acid-receptor antagonists block morphine-induced conditioned place preference in rats.
Tzschentke TM; Schmidt WJ
Neurosci Lett; 1995 Jun; 193(1):37-40. PubMed ID: 7566661
[TBL] [Abstract][Full Text] [Related]
8. Involvement of glutamatergic receptors in the nucleus cuneiformis in modulating morphine-induced antinociception in rats.
Haghparast A; Gheitasi IP; Lashgari R
Eur J Pain; 2007 Nov; 11(8):855-62. PubMed ID: 17291798
[TBL] [Abstract][Full Text] [Related]
9. The AMPA antagonists NBQX and GYKI 52466 do not counteract neuroleptic-induced catalepsy.
Zadow B; Schmidt WJ
Naunyn Schmiedebergs Arch Pharmacol; 1994 Jan; 349(1):61-5. PubMed ID: 7908126
[TBL] [Abstract][Full Text] [Related]
10. Opposite effects of NMDA and AMPA receptor blockade on catalepsy induced by dopamine receptor antagonists.
Papa SM; Engber TM; Boldry RC; Chase TN
Eur J Pharmacol; 1993 Mar; 232(2-3):247-53. PubMed ID: 8385618
[TBL] [Abstract][Full Text] [Related]
11. The competitive NMDA receptor antagonist SDZ 220-581 reverses haloperidol-induced catalepsy in rats.
McAllister KH
Eur J Pharmacol; 1996 Oct; 314(3):307-11. PubMed ID: 8957251
[TBL] [Abstract][Full Text] [Related]
12. Behavioural and neurochemical interactions of the AMPA antagonist GYKI 52466 and the non-competitive NMDA antagonist dizocilpine in rats.
Bubser M; Tzschentke T; Hauber W
J Neural Transm Gen Sect; 1995; 101(1-3):115-26. PubMed ID: 8695042
[TBL] [Abstract][Full Text] [Related]
13. Effects of competitive and non-competitive NMDA receptor antagonists on dopamine output in the shell and core subdivisions of the nucleus accumbens.
Marcus MM; Mathé JM; Nomikos GG; Svensson TH
Neuropharmacology; 2001 Mar; 40(4):482-90. PubMed ID: 11249957
[TBL] [Abstract][Full Text] [Related]
14. Excessive release of [3H]noradrenaline and glutamate in response to simulation of ischemic conditions in rat spinal cord slice preparation: effect of NMDA and AMPA receptor antagonists.
Nakai T; Milusheva E; Baranyi M; Uchihashi Y; Satoh T; Vizi ES
Eur J Pharmacol; 1999 Feb; 366(2-3):143-50. PubMed ID: 10082194
[TBL] [Abstract][Full Text] [Related]
15. NMDA receptor antagonism, but not AMPA receptor antagonism attenuates induced ischaemic tolerance in the gerbil hippocampus.
Bond A; Lodge D; Hicks CA; Ward MA; O'Neill MJ
Eur J Pharmacol; 1999 Sep; 380(2-3):91-9. PubMed ID: 10513567
[TBL] [Abstract][Full Text] [Related]
16. Lowered brain stimulation reward thresholds in rats treated with a combination of caffeine and N-methyl-D-aspartate but not alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate or metabotropic glutamate receptor-5 receptor antagonists.
Bespalov A; Dravolina O; Belozertseva I; Adamcio B; Zvartau E
Behav Pharmacol; 2006 Jun; 17(4):295-302. PubMed ID: 16914947
[TBL] [Abstract][Full Text] [Related]
17. The depressant effect of GYKI 52466 on spinal reflex transmission in rats is mediated via non-NMDA and benzodiazepine receptors.
Block F; Schwarz M
Eur J Pharmacol; 1994 Apr; 256(2):149-53. PubMed ID: 8050465
[TBL] [Abstract][Full Text] [Related]
18. Some central effects of GYKI 52466, a non-competitive AMPA receptor antagonist.
Maj J; Rogóz Z; Skuza G; Kołodziejczyk K
Pol J Pharmacol; 1995; 47(6):501-7. PubMed ID: 8868372
[TBL] [Abstract][Full Text] [Related]
19. N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4- isoxazoleproprionate (AMPA) glutamate-receptor antagonists have different interactions with the discriminative stimuli of abused drugs.
Jackson A; Brown G; Stephens DN
Psychopharmacology (Berl); 1996 Dec; 128(3):320-7. PubMed ID: 8972552
[TBL] [Abstract][Full Text] [Related]
20. Riluzole, a glutamate release inhibitor, and motor behavior.
Kretschmer BD; Kratzer U; Schmidt WJ
Naunyn Schmiedebergs Arch Pharmacol; 1998 Aug; 358(2):181-90. PubMed ID: 9750003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
